Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181227 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
A Phase 2 study, sponsored by Aviceda Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT06181227: Clinical Trial Phase 2 study, sponsored by Aviceda Therapeutics.
NCT06181227 is a Phase 2 study that was terminated before completion, run by Aviceda Therapeutics. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06181227, a Phase 2 study, was terminated before completion, sponsored by Aviceda Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
Primary Outcome
Number of participants with any evidence of serious adverse events as assessed by ocular examination
Interventions
- DRUG AVD-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2024-04-05 |
| Phase | Phase 2 |
Why NCT06181227 stopped before completion
NCT06181227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which AVD-104 is the first listed.
NCT06181227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06181227 about?
NCT06181227 is a clinical study titled "A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema". A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
What is the current status of trial NCT06181227?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-11-30. Estimated completion is 2024-04-05.
What interventions are being tested in trial NCT06181227?
The interventions under investigation include: AVD-104 (DRUG).
Who is sponsoring clinical trial NCT06181227?
This trial is sponsored by Aviceda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06181227's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI